Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

Bevacizumab, an antibody against vascular endothelial growth factor (VEGF), is a promising, yet controversial, drug in human glioblastoma treatment (GBM). Its effects on tumor burden, recurrence, and vascular physiology are unclear. We therefore determined the tumor response to bevacizumab at the ph...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Keunen, Olivier, Johansson, Mikael, Oudin, Anaïs, Sanzey, Morgane, Rahim, Siti A. Abdul, Fack, Fred, Thorsen, Frits, Taxt, Torfinn, Bartos, Michal, Jirik, Radovan, Miletic, Hrvoje, Wang, Jian, Stieber, Daniel, Stuhr, Linda, Moen, Ingrid, Rygh, Cecilie Brekke, Bjerkvig, Rolf, Niclou, Simone P.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: National Academy of Sciences 2011
Gaiak:
Biological Sciences
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3048093/
https://ncbi.nlm.nih.gov/pubmed/21321221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1014480108
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak